Key facts
- It has raised $9.6M; the latest was Early Stage VC in Sep 2025.
- Notable investors include Zhongshan Finance Investment, Baheal Pharmaceutical Group, Baiyang Capital, HuaChuang Securities, Niche Investment — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for RabPharma
- ·The full record, as it builds
Funding rounds
No funding rounds for RabPharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RabPharma
Provider and developer of drugs and treatments designed for bone diseases. The company focuses on research and development of peptide-drug conjugate (PDC) and innovative drugs for osteonecrosis, enabling patients with better treatments.
- Sector
- Healthcare
- HQ
- Zhongshan, China
- Founded
- 2021
- Employees
- 21
- Website
- rabpharma.com/
- Ownership
- Privately Held (backing)
RabPharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RabPharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RabPharma in its N-PORT filings yet. We sweep new filings monthly.